health
TROP2 cell-location pattern may predict datopotamab benefit in lung cancer
A retrospective analysis found that a computational measure of TROP2’s location within tumour cells was associated with longer outcomes from datopotamab deruxtecan in a defined group of patients with non-small-cell lung cancer. Prospective studies are needed to establish its use in treatment selection.